Accuray Inc. - Margin operasi ARAY

Logo perusahaan publik Accuray Incorporated (ARAY)

The expansion of the CyberKnife network and the implementation of AI planning are driving growth, forcing Accuray Incorporated (ARAY) to flexibly adjust pricing to win tenders. The operating profit margin clearly demonstrates this dependency, where the -0.60 indicator determines the magnitude of the metric. Financial stability is further bolstered by the delivery of robotic systems to major medical centers, through which the company generates revenue from high-precision treatment.

ARAY - Rentabilitas dodolan operasi Accuray Inc ing rentang 04.07.2022 - 19.11.2026

ARAY (accuray.com): rincian analitis lan laporan miturut indikator

- rega lan prakiraan konsensus rega:
Analisis umum perusahaan:Accuray, Inc., ARAY
Produk dadi Accuray Incorporated

Accuray Incorporated specializes in developing high-tech robotic systems for precision radiation therapy. Operating margin measures the efficiency of the core business, reflecting the share of profit before taxes and interest obligations in total revenue. For an investor, this metric serves as an indicator of the company's ability to monetize R&D investments in AI algorithms. Analyzing the current operating margin value on GURU.Markets allows for an assessment of the balance between innovative development and operational profitability. The trend of this indicator reveals risks or the potential for growth in the business's market capitalization.

Analisis perusahaan pesaing

Rentabilitas operasi BeiGene Ltd|Halozyme Therapeutics - Margin bathi operasi|Margin dodolan operasi RVMD (Revolution Medicines Corp)|Rasio bathi operasi AAPG|Rentabilitas operasi CG Oncology Therapeutics CGON|Tingkat bathi operasi URGN|BCAX: Margin dodolan operasi|PSNL: Rentabilitas operasi|Erasca (ERAS) - Rentabilitas operasi|DCTH - Rentabilitas kegiatan operasi|YMAB (Y-mAbs Corp) - Margin operasi|Margin dodolan operasi Aura Biosciences (AURA)|Rentabilitas operasi Candel Therapeutics Inc. (CADL)|SLS (SELLAS Life Sciences Group, Inc.) - Tingkat bathi operasi|Rentabilitas operasi Actuate Therapeutics, Inc. ACTU|citiusonc.com - Rentabilitas operasi|TuHURA Biosciences Inc. - Margin operasi|TARA - Margin operasi|FATE (Fate Therapeutics) - Margin dodolan operasi|Margin dodolan operasi Aadi Bioscience, Inc.|Margin dodolan operasi TCRX|Rentabilitas operasi CSBR|Margin operasi XBIT|Rentabilitas kegiatan operasi CEL-SCI Corp.|Rentabilitas operasi ostherapies.com OSTX|RADX: Rentabilitas dodolan miturut bathi operasi|ARTV: Margin dodolan operasi|ANL (Adlai Nortye) - Rentabilitas dodolan miturut bathi operasi|Veru (VERU) - Rentabilitas operasi|Margin dodolan operasi Tempest Therapeutics Inc|Rentabilitas operasi Xilio Therapeutics|Rentabilitas dodolan miturut bathi operasi RENB (Renovaro Inc.)|Rentabilitas operasi Mural Oncology PLC (MURA)|Margin operasi Kairos Pharma (KAPA)|Rentabilitas operasi onkuretherapeutics.com OKUR|GDTC: Rentabilitas dodolan miturut bathi operasi|CRIS: Margin dodolan operasi|apollomicsinc.com (APLM) - Margin dodolan operasi|THAR: Margin operasi|Margin dodolan operasi Advanced Biomed Inc.|Margin dodolan operasi GNPX|Rentabilitas dodolan miturut bathi operasi CLDI (Calidi Biotherapeutics)|Margin operasi SBFM|Xenetic Biosciences, Inc. - Rentabilitas dodolan miturut bathi operasi|Rentabilitas operasi Salarius Pharmaceuticals SLRX|Margin operasi purple-biotech.com PPBT|AONC - Rentabilitas operasi|BGNE: Rentabilitas operasi|CKPT: Margin operasi|Elevation Oncology - Tingkat bathi operasi|ICAD (iCAD) - Margin operasi|IKNA: Tingkat bathi operasi|Rentabilitas operasi Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Tingkat bathi operasi|Rentabilitas operasi MorphoSys Corporation MOR|NAYA: Rentabilitas dodolan miturut bathi operasi|Ascentage Pharma Group International - Margin operasi